Ignite Creation Date:
2024-05-06 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05231122
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2022-01-24
Brief Title:
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Ovarian Clear Cell Adenocarcinoma |
| Platinum-Sensitive Ovarian Carcinoma |
| Recurrent Endometrial Serous Adenocarcinoma |
| Recurrent Fallopian Tube Carcinoma |
| Recurrent Fallopian Tube Endometrioid Adenocarcinoma |
| Recurrent Fallopian Tube Serous Adenocarcinoma |
| Recurrent Ovarian Carcinoma |
| Recurrent Ovarian Clear Cell Adenocarcinoma |
| Recurrent Ovarian Endometrioid Adenocarcinoma |
| Recurrent Ovarian Serous Adenocarcinoma |
| Recurrent Platinum-Resistant Ovarian Carcinoma |
| Recurrent Primary Peritoneal Carcinoma |
| Recurrent Primary Peritoneal Clear Cell Adenocarcinoma |
| Recurrent Primary Peritoneal Endometrioid Adenocarcinoma |
| Recurrent Primary Peritoneal Serous Adenocarcinoma |
Keywords: